Bausch Health Companies Inc (NYSE:BHC)

8.39
Delayed Data
As of Sep 21
 +0.05 / +0.60%
Today’s Change
5.57
Today|||52-Week Range
10.23
+33.60%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$3.1B

Company Description

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Contact Information

Bausch Health Cos., Inc.
2150 St. Elzéar Boulevard West
Laval Qubec H7L 4A8
P:(514) 744-6792
Investor Relations:
(514) 856-3855

Employees

Shareholders

Other institutional59.30%
Mutual fund holders14.25%
Individual stakeholders13.76%

Top Executives

Thomas J. AppioChief Executive Officer & Director
Mirza DautbegovicChief Operating Officer & Senior Vice President
Tom G. VadakethChief Financial Officer & Executive Vice President
Tage RamakrishnaChief Medical Officer, President-R&D
Seana-Lyn CarsonExecutive Vice President & General Counsel